Patisiran is indicated for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR) in adults. The Food and Drug Administration (FDA) of the United States of America approved this therapeutic usage in August 2018. It is in the RNA interference therapeutics class of drugs. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR), wild-type of transthyretin-mediated amyloidosis (ATTR), and related conditions.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/137854
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
Nursing: 2.0 hours
Pharmacy: 2.0 hours - MOC Credit Details: ABS - 2.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 2.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABTS - 2.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 2.0 Point; Credit Type(s): Self-Assessment (ABS)
ABTS - 2.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adult Cardiac, Advanced Heart Failure and Transplant Cardiology, All Practice Areas (e.g. ethics), Cardiothoracic, Cardiovascular, Cardiovascular Disease, General Surgery, Geriatric Medicine, Hematology, Hospital Medicine, Medical Oncology, Nephrology, Pulmonary Disease, Rheumatology